Mezaton (phenylephrine hydrochloride) ampoules 1% 1ml. №10


Indication: arterial hypotension. shock (traumatic, toxic). vascular insufficiency at overdose of vasodilators. as a vasoconstrictor during local anesthesia.



Mezaton composition
active substance: phenylephrine;
1 ml of solution contains phenylephrine hydrochloride 10 mg;
Excipients: glycerin, water for injections.

Dosage form
Solution for injection.

Pharmacological properties
Mezaton is an α1-adrenomimetic that has a negligible effect on the b-adrenoceptors of the heart. It is not a catecholamine because it contains only one hydroxyl group in the aromatic nucleus. Causes narrowing of arterioles and increase in blood pressure (with possible reflex bradycardia). Compared to norepinephrine and epinephrine, it raises blood pressure less sharply, but lasts longer because it is less susceptible to catechol-o-methyltransferase. Does not increase the minute volume of blood. The action begins immediately after administration and lasts for 5-20 minutes after intravenous administration. When administered subcutaneously, the effect lasts up to 50 minutes. Intramuscular administration – up to 1-2 hours.


  • arterial hypotension.
  • shock (traumatic, toxic).
  • vascular insufficiency at overdose of vasodilators.
  • as a vasoconstrictor during local anesthesia.

Hypersensitivity to the components of the drug. All types of arterial hypertension, cardiosclerosis, halothane or cyclopropane anesthesia, hypertrophic cardiomyopathy, pheochromocytoma, ventricular fibrillation, occlusive vascular diseases: arterial thromboembolism, atherosclerosis, obliterative thrombocytopenia (thrombocytopenia) , tachyarrhythmia, metabolic acidosis, hypercapnia, hypoxia, angle-closure glaucoma, severe stenosis of the aortic orifice, acute myocardial infarction, porphyria, glucose-6-phosphate dehydrogenase deficiency, diabetes mellitus. Patients with prostate disease who are at increased risk of urinary retention. Concomitant use with MAO inhibitors and for 14 days after discontinuation of their use. Elderly patients.

The drug should not be used in children.

Use during pregnancy or breastfeeding
The drug is contraindicated during pregnancy or breastfeeding.
If you need to use the drug should stop breastfeeding.
Ability to influence the speed of reaction when driving a car or other machinery. When using the drug is contraindicated to drive a car or work with other dangerous mechanisms.

Method of application and dosage
The drug should be administered to adults intravenously, intramuscularly and subcutaneously. A single dose of the drug when administered intravenously in case of collapse – 0.1-0.3-0.5 ml of 1% solution. When administered intravenously, a single dose of the drug should be diluted in 20 ml of 5% glucose solution or 0.9% sodium chloride solution, administered slowly, jet. If necessary, repeat the introduction.
The drug is allowed to be administered intravenously, for which 1 ml of 1% solution of Mezaton is dissolved in 250-500 ml of 5% glucose solution.
For intramuscular and subcutaneous administration, the single dose for adults is 0.3-1 ml of 1% solution.
Under local anesthesia, add 0.3-0.5 ml of 1% solution per 10 ml of anesthetic solution.
To prevent the “withdrawal syndrome”, after a long infusion of the drug (repeated reduction of blood pressure in contrast to the drug), the dose should be reduced gradually.
The infusion should be resumed if systolic blood pressure drops to 70-80 mm Hg. Art.
Higher doses for adults with intramuscular and subcutaneous administration: single – 10 mg, daily – 50 mg. The highest dose for intravenous administration to adults: single – 5 mg, daily – 25 mg.

Symptoms: ventricular arrhythmia, short paroxysms of ventricular tachycardia, heaviness in the head or extremities, excessive increase in blood pressure.
Treatment: intravenous short-acting α-blockers (phentolamine). In case of cardiac arrhythmia, enter b-blockers (propranolol).

Side effects:

  • From the cardiovascular system: angina, bradycardia, increase or decrease in blood pressure, tachycardia, ventricular arrhythmias (especially when used in high doses), increased heart rate.
  • From the nervous system: headache, irritability, motor restlessness, dizziness, horror, anxiety, weakness, pale skin, tremor, convulsions, hemorrhage into the brain.
  • From the digestive tract: nausea, vomiting.
  • From the respiratory system: dyspnea.
  • Allergic reactions: skin rash, itching.
  • On the part of the visual organs: eye pain, conjunctival hyperemia, allergic reaction of the eyelids, mydriasis.
  • From the urinary system: urinary incontinence, urinary retention.
  • Others: increased sweating, hypersalivation, tingling and cooling of the extremities, hot flashes, hyperglycemia.

Expiration date
4 years.

Storage conditions
Store Mezaton at a temperature not exceeding 25 ° C in the original package.
Keep out of reach of children.